Bellicum Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

Author's Avatar
May 30, 2018
Article's Main Image

HOUSTON, May 30, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (BLCM, Financial), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6 at 2:00 p.m. EDT in New York, NY.

A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.

AboutBellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.

Source: Bellicum Pharmaceuticals

ti?nf=NzI5NDk1NCMyMzQ0NDAzIzIwMTY2OTU=